PE20070192A1 - Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina - Google Patents

Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Info

Publication number
PE20070192A1
PE20070192A1 PE2006000833A PE2006000833A PE20070192A1 PE 20070192 A1 PE20070192 A1 PE 20070192A1 PE 2006000833 A PE2006000833 A PE 2006000833A PE 2006000833 A PE2006000833 A PE 2006000833A PE 20070192 A1 PE20070192 A1 PE 20070192A1
Authority
PE
Peru
Prior art keywords
succinate
demethylvenlafaxine
dosage forms
release dosage
available oral
Prior art date
Application number
PE2006000833A
Other languages
English (en)
Spanish (es)
Inventor
Syed Shah
Mahdi B Fawzi
Christopher Richard Dioro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070192A1 publication Critical patent/PE20070192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2006000833A 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina PE20070192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
PE20070192A1 true PE20070192A1 (es) 2007-03-16

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000833A PE20070192A1 (es) 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Country Status (20)

Country Link
US (1) US20070014859A1 (enExample)
EP (1) EP1904040A2 (enExample)
JP (1) JP2009501233A (enExample)
KR (1) KR20080025405A (enExample)
CN (1) CN101247791A (enExample)
AR (1) AR054833A1 (enExample)
AU (1) AU2006270315A1 (enExample)
BR (1) BRPI0613484A2 (enExample)
CA (1) CA2612960A1 (enExample)
CR (1) CR9626A (enExample)
EC (1) ECSP088106A (enExample)
GT (1) GT200600307A (enExample)
IL (1) IL188313A0 (enExample)
MX (1) MX2008000666A (enExample)
NO (1) NO20080088L (enExample)
PE (1) PE20070192A1 (enExample)
RU (1) RU2007148195A (enExample)
SV (1) SV2008002612A (enExample)
TW (1) TW200740427A (enExample)
WO (1) WO2007011619A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
ES2335919T3 (es) * 2005-03-31 2010-04-06 Wyeth Producto de combinacion de o-desmetilvenlafaxina y bazedosifeno, y sus usos.
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007067501A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
US20100330172A1 (en) * 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20110027324A1 (en) * 2007-12-10 2011-02-03 Wyeth Llc O-desmethyl-venlafaxine for treating major depressive disorder
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) * 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
EP2498751B1 (en) * 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP2552419A2 (en) * 2010-03-31 2013-02-06 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
WO2005077340A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
WO2007011619A2 (en) 2007-01-25
CR9626A (es) 2008-04-10
AR054833A1 (es) 2007-07-18
CA2612960A1 (en) 2007-01-25
GT200600307A (es) 2008-04-24
IL188313A0 (en) 2008-04-13
SV2008002612A (es) 2008-08-29
WO2007011619A3 (en) 2007-06-21
US20070014859A1 (en) 2007-01-18
RU2007148195A (ru) 2009-08-20
BRPI0613484A2 (pt) 2016-11-16
TW200740427A (en) 2007-11-01
JP2009501233A (ja) 2009-01-15
EP1904040A2 (en) 2008-04-02
AU2006270315A1 (en) 2007-01-25
KR20080025405A (ko) 2008-03-20
NO20080088L (no) 2008-04-02
ECSP088106A (es) 2008-02-20
CN101247791A (zh) 2008-08-20
MX2008000666A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
PE20091971A1 (es) Formulaciones orales de analogos de citidina y metodos de uso de los mismos
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
PE20070458A1 (es) Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
TW200626558A (en) Indazolone derivatives
MX2009004439A (es) Composicion de ibuprofeno.
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
UA87841C2 (ru) Композиция, которая содержит амброксол, для местного применения
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE
TW200621312A (en) Oral solid dosage forms containing a low dose of estradiol
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
PE20050188A1 (es) Monohidrato de 4-ciclopentilresorcinol como agente de despigmentacion

Legal Events

Date Code Title Description
FX Voluntary withdrawal